Is LetsGetChecked profitable in 2026?

No audited financials are public. LetsGetChecked is private, last confirmed unicorn valuation of $1B+ came from a $150M Series D in June 2021, and 2025 saw a 38.6% headcount drop per Revelio Labs, suggesting cost pressure rather than confirmed profitability.

Who owns LetsGetChecked now?

Since May 21, 2025, LetsGetChecked operates as a brand under Fuze Health, a holding company formed by combining LetsGetChecked with Truepill (acquired for $525M, closed October 1, 2024) and digital pharmacy Alto.

Could AI replace LetsGetChecked's business?

Not directly. LetsGetChecked owns CLIA-certified labs, FDA clearances like its ImPress lancing device and November 2023 at-home Chlamydia/Gonorrhea authorization, and a regulated clinician network, none of which pure software AI can replicate without matching physical and regulatory investment.

Who is LetsGetChecked's biggest competitor?

Everlywell/Everly Health is the most cited rival, claiming 35M+ tests delivered as of March 2026 versus LetsGetChecked's own claim of 10M+ cumulative tests. Quest Diagnostics and Labcorp, which already own larger lab infrastructure, are also expanding into direct-to-consumer testing.

Has LetsGetChecked faced legal trouble?

Yes. TruthCures et al. v. LetsGetChecked, Inc. was filed June 21, 2023 in Massachusetts, alleging its at-home Lyme disease test is shockingly inaccurate and misrepresents diagnostic reliability; the case's resolution status is unconfirmed as of 2026.

What is LetsGetChecked's valuation?

LetsGetChecked reached unicorn status, valued over $1B, in June 2021 following a $150M Series D led by Casdin Capital with participation from Optum Ventures and Illumina Ventures. No confirmed new priced round at or above $1B has been reported since.

United States · subsidiary of Fuze Health · United States

LetsGetChecked

At-home lab testing company now folded into Fuze Health with Truepill and Alto.

Protection under test

Assessed 29 July 2026 · Evidence as of 29 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 29 July 2026 · Checkable from end of 2026 · Every call on the record Checkpoint: Fuze Health first audited post-merger financial disclosure or a new priced funding round

The call

LetsGetChecked has the labs and FDA clearances that keep it in the game, but its merger debt, shrinking headcount, and unsettled Lyme litigation leave the outcome genuinely unclear.

LetsGetChecked lets people order lab tests online and get results from home instead of visiting a clinic. It has real advantages like FDA approvals and its own labs, but these aren't hard to copy: Quest Diagnostics and Labcorp already own identical capabilities and are selling online too, while Everlywell processes more tests overall. The company just merged with two others to form Fuze Health, cut 38 percent of its staff, and is dealing with lawsuits about Lyme disease tests and government scrutiny of its health-data practices, so the next few quarters will show whether the merger actually works or creates more chaos.

Why

AI pressure: None apparent. AI symptom-checkers and telehealth triage apps could steer people away from mail-in kits, but no direct product targets this niche yet. Could AI do the core job? Unlikely.

Bigger players: Quest Diagnostics, Labcorp. Both already run live direct-to-consumer testing arms with the same lab infrastructure and no legal barrier stopping them. Could a giant copy it? Yes, easily.

What protects it. CLIA-certified labs, FDA clearances, and a clinician network that a pure software rival cannot replicate overnight.

What would change this call

Fuze Health publishes audited 2025 or 2026 revenue figures or announces a new priced funding round by end of 2026. Would show the merger stabilized finances instead of masking a down round or distress.
Headcount trend for Q1-Q2 2026 either stabilizes near 960 or keeps falling. Shows whether the 38% 2025 cut was a one-time reset or ongoing contraction.
Outcome or settlement of the Lyme disease class-action lawsuit becomes public. Would reveal financial liability and reputational damage to the core diagnostics brand.

Key numbers

$525M Truepill acquisition, partly debt-financed (2024-10-01)
38% headcount drop, 1,564 to 960 staff (2025)
$150M convertible note sits senior to equity (2024-10-01)

Named risks

FTC enforcement wave against DTC health data sharing and subscription billing models. Severity: high
Post-merger integration instability across three-way Fuze Health roll-up formed May 2025. Severity: high
Active TruthCures class action alleging inaccurate Lyme disease test results. Severity: medium
38.6% headcount decline from 2023 to Q4 2025 signaling possible cost distress. Severity: medium
Debt-funded $525M Truepill acquisition increasing leverage exposure. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Everlywell	losing to	Claims 35M+ tests delivered as of 2026-03-16 vs LetsGetChecked's own 10M+ cumulative tests claim
Quest Diagnostics	losing to	Owns larger lab infrastructure and now offers direct-to-consumer test ordering as of 2025-02-10
Labcorp	losing to	Already operates equivalent CLIA lab assets and entered DTC testing, per 2025-02-10 reporting
Hims & Hers	contesting	FTC sued Hims & Hers July 29, 2026 over health data and subscription practices shared by DTC health peers
23andMe	contesting	Adjacent genomics competitor, itself financially distressed as of 2026-07-21 reporting

Questions people ask

Is LetsGetChecked profitable in 2026?: No audited financials are public. LetsGetChecked is private, last confirmed unicorn valuation of $1B+ came from a $150M Series D in June 2021, and 2025 saw a 38.6% headcount drop per Revelio Labs, suggesting cost pressure rather than confirmed profitability.
Who owns LetsGetChecked now?: Since May 21, 2025, LetsGetChecked operates as a brand under Fuze Health, a holding company formed by combining LetsGetChecked with Truepill (acquired for $525M, closed October 1, 2024) and digital pharmacy Alto.
Could AI replace LetsGetChecked's business?: Not directly. LetsGetChecked owns CLIA-certified labs, FDA clearances like its ImPress lancing device and November 2023 at-home Chlamydia/Gonorrhea authorization, and a regulated clinician network, none of which pure software AI can replicate without matching physical and regulatory investment.
Who is LetsGetChecked's biggest competitor?: Everlywell/Everly Health is the most cited rival, claiming 35M+ tests delivered as of March 2026 versus LetsGetChecked's own claim of 10M+ cumulative tests. Quest Diagnostics and Labcorp, which already own larger lab infrastructure, are also expanding into direct-to-consumer testing.
Has LetsGetChecked faced legal trouble?: Yes. TruthCures et al. v. LetsGetChecked, Inc. was filed June 21, 2023 in Massachusetts, alleging its at-home Lyme disease test is shockingly inaccurate and misrepresents diagnostic reliability; the case's resolution status is unconfirmed as of 2026.
What is LetsGetChecked's valuation?: LetsGetChecked reached unicorn status, valued over $1B, in June 2021 following a $150M Series D led by Casdin Capital with participation from Optum Ventures and Illumina Ventures. No confirmed new priced round at or above $1B has been reported since.

Timeline

2026-07-29FTC sues Hims & Hers over health data sharing and subscription billing, sector-wide DTC health risk signal
2025-12Revelio Labs estimates LetsGetChecked/Fuze headcount at 960, down 38.6% from 1,564 in 2023
2025-05-21Truepill, LetsGetChecked and Alto rebrand as combined holding company Fuze Health
2024-10-01LetsGetChecked completes $525M acquisition of digital pharmacy Truepill
2024-08-21Truepill deal announced, partly financed via $150M convertible note
2024-02LetsGetChecked launches myGeneticScreen genetic screening panel in the US
2023-11FDA authorizes LetsGetChecked at-home Chlamydia and Gonorrhea test
2023-06-21TruthCures class action filed against LetsGetChecked over Lyme test accuracy
2023-06-10Series E of roughly $73.9M reported, led by Optum Ventures
2021-06-08LetsGetChecked hits unicorn status via $150M Series D led by Casdin Capital

Revision history

29 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Ford Motor Whirlpool Solventum